<DOC>
	<DOCNO>NCT02726399</DOCNO>
	<brief_summary>The purpose study compare good bad effect use ramucirumab along usual trastuzumab chemotherapy use usual chemotherapy trastuzumab alone .</brief_summary>
	<brief_title>Ramucirumab With Trastuzumab Capecitabine/Cisplatin Patients With Metastatic HER2-Positive Gastroesophageal Junction Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must pathologically cytologically MSKCC confirm diagnosis gastric GEJ adenocarcinoma . Patients must Stage IV gastric GEJ adenocarcinoma HER2 overexpression and/or amplification determine next generation sequence assay , immunohistochemistry ( IHC 3+ ) fluorescent situ hybridization ( FISH+ define HER2 : CEP17 ratio ≥ 2.0 ) . MSKCC confirmation HER2 status mandatory prior enrollment treatment study . For patient outside HER2 testing , sufficient tissue available HER2 testing repeat MSKCC purpose analysis impact patient 's eligibility . Available archival tumor tissue submit MSKCC IMPACT analysis , require prior registration . Note : tissue deplete , patient still eligible discussion PI . Patients must disease evaluate radiographically . This may measurable disease nonmeasurable disease per RECIST 1.1 . Patients may receive prior chemotherapy Stage IV disease . Patients may receive prior adjuvant therapy ( chemotherapy and/or chemoradiation ) 6 month elapse end adjuvant therapy registration . Age 18 year old . ECOG performance status 01 . Peripheral neuropathy ≤ grade 1 Patients adequate hepatic function define total bilirubin ≤1.5 time upper limit institutional normal value ( ULN ) mg/dL ( except patient Gilbert 's disease ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 time ULN ≤ 5.0 time ULN set liver metastasis . Patients adequate hematologic function , evidence absolute neutrophil count ( ANC ) ≥1500/μL , hemoglobin ≥9 g/dL ( 5.58 mmol/L ) , platelets ≥100,000/μL . Patients adequate renal function define calculated creatinine clearance ≥60 mL/minute use CockcroftGaul formula equivalent method . Patients whose urinary protein ≤2+ routine urinalysis ( UA ; routine analysis &gt; 2+ , 24hour urine collection protein must demonstrate &lt; 2g protein 24 hour allow participation protocol ) . Patients must adequate coagulation function define International Normalized Ratio ( INR ) ≤1.5 partial thromboplastin time ( PTT ) ≤ 5 second ULN ( unless receive anticoagulation therapy ) . Patients fulldose anticoagulation must stable dose ( minimum duration 14 day ) oral anticoagulant low molecular weight heparin . Patients receive warfarin must switch low molecular weight heparin achieve stable coagulation profile prior randomization . Patients , must postmenopausal , surgically sterile , use effective contraception ( hormonal barrier method ) . Female patient childbearing potential must negative serum pregnancy test within 7 day study entry . Patients uncontrolled poorlycontrolled hypertension ( &gt; 160 mmHg systolic &gt; 100 mmHg diastolic &gt; 4 week ) despite standard medical management . Patients receive concurrent anticancer therapy investigational agent intention treat gastric/GEJ cancer . Previously receive trastuzumab part regimen metastatic set evidence progression . 89Zrtrastuzumab use imaging agent 89Zrtrastuzumab PET permit . Patients : Cirrhosis level ChildPugh B ( bad ) Cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . Clinically meaningful ascites define ascites cirrhosis require diuretic paracentesis . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II . Active coronary artery disease . Left ventricular function &lt; 50 % . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . Patients experience arterial thromboembolic event , include limited myocardial infarction , transient ischemic attack , cerebrovascular accident , unstable angina , within 6 month prior enrollment . Patients receive chronic antiplatelet therapy , include dipyridamole clopidogrel , similar agent . Oncedaily aspirin ( maximum dose 325 mg/day ) , nonsteroidal antiinflammatory drug ( NSAIDs , include ibuprofen , naproxen , others ) use permit . Evidence history bleed diathesis coagulopathy . Patients experience Grade 34 GI bleeding within 3 month prior enrolment . Unwillingness give write informed consent , unwillingness participate , inability comply protocol duration study . Patients prior trastuzumab treatment . Patients know active brain central nervous system metastasis , include leptomeningeal disease . Patients treat asymptomatic brain metastasis may eligible discussion PI . Patients pregnant breastfeeding . Patients serious nonhealing wound , ulcer , bone fracture within 28 day prior enrollment . Patients may major surgical procedure within 2 week registration . Patients elective plan major surgery perform course clinical trial.Minor surgery/subcutaneous venous access device placement within 7 day prior first dose protocol therapy permit . Patients may radiation within 28 day prior first dose week registration . Patients may medical condition reason , investigator 's opinion , make patient unstable participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ramucirumab</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>HER2-Positive</keyword>
	<keyword>15-301</keyword>
</DOC>